Markets:

Overview

News

Currencies

International

Treasuries

Repligen Corporation - Common Stock (NQ:RGEN)

146.29 +2.05 (+1.42%)

Streaming Delayed Price Updated: 11:42 AM EDT, Jul 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Repligen Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

3 Reasons RGEN is Risky and 1 Stock to Buy Instead

July 08, 2026

Over the last six months, Repligen’s shares have sunk to $139.83, producing a disappointing 16% loss - a stark contrast to the S&P 500’s 9% gain. This might ...

Via StockStory

Topics Stocks Supply Chain

2 High-Flying Stocks on Our Watchlist and 1 We Find Risky

June 25, 2026

Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo...

Via StockStory

2 Profitable Stocks on Our Watchlist and 1 Facing Challenges

June 19, 2026

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

Via StockStory

3 Out-of-Favor Stocks We Keep Off Our Radar

May 22, 2026

Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a co...

Via StockStory

Repligen Corp (NASDAQ:RGEN) Sees Pre-Market Gain After Q1 Earnings Beat Offsets Slight Revenue Miss ↗

May 05, 2026

Via Chartmill

Topics Earnings

Q1 Rundown: Repligen (NASDAQ:RGEN) Vs Other Drug Development Inputs & Services Stocks

May 18, 2026

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services ind...

Via StockStory

Why Repligen (RGEN) Stock Is Trading Up Today

May 15, 2026

What Happened? Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 2.9% in the afternoon session after RBC Capital resumed co...

Via StockStory

Topics Artificial Intelligence Economy

1 Growth Stock with Explosive Upside and 2 Facing Headwinds

May 15, 2026

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr...

Via StockStory

Repligen, AdaptHealth, and IQVIA Stocks Trade Down, What You Need To Know

May 13, 2026

What Happened? A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with servi...

Via StockStory

Topics Economy

5 Revealing Analyst Questions From Repligen’s Q1 Earnings Call

May 12, 2026

Repligen’s first quarter results were met positively by the market, reflecting solid execution across core product lines and robust demand in both analytics ...

Via StockStory

Topics Earnings

3 Small-Cap Stocks We Steer Clear Of

May 12, 2026

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...

Via StockStory

Repligen (RGEN) Shares Skyrocket, What You Need To Know

May 05, 2026

What Happened? Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 7.3% in the morning session after the company reported fir...

Via StockStory

Topics Artificial Intelligence Earnings Regulatory Compliance

Repligen (RGEN) Q1 2026 Earnings Call Transcript ↗

May 05, 2026

Repligen (RGEN) Q1 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Repligen’s (NASDAQ:RGEN) Q1 CY2026 Sales Beat Estimates

May 05, 2026

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 14.8% ...

Via StockStory

Topics Earnings

Repligen (RGEN) Q1 Earnings Report Preview: What To Look For

May 03, 2026

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be announcing earnings results this Tuesday before the bell. Here’s what investors sh...

Via StockStory

Topics Artificial Intelligence

Why Repligen (RGEN) Shares Are Plunging Today

April 22, 2026

What Happened? Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) fell 5.3% in the afternoon session after an SEC filing revealed t...

Via StockStory

Topics Economy Regulatory Compliance

Envista, Baxter, Surgery Partners, Charles River Laboratories, and Repligen Stocks Trade Up, What You Need To Know

April 17, 2026

What Happened? A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a cooling of global logistics and ener...

Via StockStory

Topics Economy

1 of Wall Street’s Favorite Stock to Own for Decades and 2 We Avoid

April 16, 2026

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...

Via StockStory

1 Cash-Producing Stock Worth Your Attention and 2 We Avoid

April 14, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Via StockStory

RadNet, Evolent Health, Illumina, Charles River Laboratories, and Repligen Stocks Trade Down, What You Need To Know

March 27, 2026

What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...

Via StockStory

Topics Economy Government Stocks

1 High-Flying Stock with Solid Fundamentals and 2 We Avoid

March 24, 2026

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ...

Via StockStory

1 Cash-Heavy Stock to Target This Week and 2 We Question

March 19, 2026

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...

Via StockStory

A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack

March 15, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

2 Growth Stocks Set to Flourishand 1 We Turn Down

March 13, 2026

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr...

Via StockStory

3 Profitable Stocks We Keep Off Our Radar

March 10, 2026

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...

Via StockStory

Brown Capital Dumps 190,000 AppFolio Shares Worth $45.1 Million ↗

March 06, 2026

Via The Motley Fool

AMN Healthcare Services, RadNet, Evolent Health, Repligen, and Amphastar Pharmaceuticals Stocks Trade Down, What You Need To Know

March 06, 2026

Via StockStory

Topics Economy

3 Healthcare Stocks We’re Skeptical Of

March 02, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali...

Via StockStory

3 Reasons to Avoid RGEN and 1 Stock to Buy Instead

March 02, 2026

Repligen trades at $124.97 and has moved in lockstep with the market. Its shares have returned 7.6% over the last six months while the S&P 500 has gained 6.6...

Via StockStory

Topics Stocks Supply Chain

Privia Health, Repligen, and RadNet Shares Plummet, What You Need To Know

February 27, 2026

A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures.

Via StockStory

Topics Economy Stocks

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.